Data Foundry

Drug recalls 2023

Epi-Caine — Class II drug recall D-0130-2023

Terminated recall by Pine Pharmaceuticals, LLC, reported 2023-01-11, distributed nationwide. CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Recall numberD-0130-2023
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmPine Pharmaceuticals, LLC, Tonawanda, NY, United States
Recall initiated2022-12-22
Classified2023-01-13
Reported by FDA2023-01-11
Terminated2023-05-04
DistributedNationwide (US)
Quantity11,453 vials
Reason classescgmp
NDC69194-0948-01
Lot numbers62881, 62923, 63066, 63067, 63103, 63120, 63219, 63226, 63263, 63380, 63381, 63433, 63455, 63537, 63580, 63721, 63792, 63888, 63930, 63959, 64079, 64109, 64239
Expiration dates2022-12-25, 2022-12-26, 2023-01-01, 2023-01-02, 2023-01-03, 2023-01-08, 2023-01-09, 2023-01-15, 2023-01-16, 2023-01-17, 2023-01-22, 2023-01-23, 2023-01-29, 2023-01-31, 2023-02-05, 2023-02-06, 2023-02-07, 2023-02-13, 2023-02-14, 2023-02-21

Product

Epi-Caine, Epinephrine 0.025% Lidocaine HCL 0.75% Solution for Intraocular Injection, 1 ml, Single Dose Vial, Compounded by Pine Pharmaceuticals, 355 Riverwalk Pkwy, Tonawanda, NY 14150. NDC 69194-0948-1

Reason for recall

CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0130-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.